-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$65.33161.32% Upside
Tourmaline Bio, Inc. Frequently Asked Questions
-
What analysts cover Tourmaline Bio, Inc.?
Tourmaline Bio, Inc. has been rated by research analysts at Guggenheim, Truist Financial, Jefferies in the past 90 days.